Thomson Horstmann & Bryant Inc. boosted its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 33.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,101 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,006 shares during the period. Thomson Horstmann & Bryant Inc. owned about 0.17% of ANI Pharmaceuticals worth $1,295,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in ANIP. BNP Paribas Arbitrage SA lifted its holdings in ANI Pharmaceuticals by 44.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 664 shares during the last quarter. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $197,000. Stevens Capital Management LP bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $207,000. Dynamic Technology Lab Private Ltd bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $210,000. Finally, Violich Capital Management Inc. bought a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $217,000. 55.05% of the stock is owned by hedge funds and other institutional investors.
Shares of ANI Pharmaceuticals Inc (NASDAQ ANIP) opened at $71.06 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. The firm has a market cap of $827.35, a PE ratio of 112.79 and a beta of 2.90. ANI Pharmaceuticals Inc has a 1 year low of $42.23 and a 1 year high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.12. The firm had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.09 EPS. equities research analysts forecast that ANI Pharmaceuticals Inc will post 3.59 earnings per share for the current fiscal year.
Several equities analysts recently issued reports on ANIP shares. Canaccord Genuity set a $77.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 29th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $71.00.
ILLEGAL ACTIVITY NOTICE: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/12/thomson-horstmann-bryant-inc-has-1-30-million-position-in-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.